📰 Beigene News
Page 5 - Beigene News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Beigene. Real-time updates on events, politics, business and more.
October 13, 2023
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of zanubrutinib in combination with obinutuzumab for use in adult patients with relapsed or refractory follicular lymphoma who have previously received at least 2 lines of systemic treatment.
October 9, 2023
BeiGene, Ltd. (NASDAQ:BGNE – Get Free Report) has been assigned an average rating of “Moderate Buy” from the twelve research firms that are presently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold rating and ten have issued a buy rating on the company. The average 1-year target price among […]
October 7, 2023
BeiGene, Ltd. (NASDAQ:BGNE – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the twelve analysts that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and ten have assigned a buy recommendation to the company. The average 12 month target price among brokerages […]
September 26, 2023
BeiGene (NASDAQ:BGNE – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Monday. BGNE has been the subject of several other reports. 22nd Century Group reaffirmed a “downgrade” rating on shares of BeiGene in a research note on Friday, […]
September 25, 2023
BeiGene (NASDAQ:BGNE – Free Report) had its price objective hoisted by Citigroup from $285.00 to $290.00 in a research note released on Thursday morning, Marketbeat.com reports. Citigroup currently has a buy rating on the stock. A number of other analysts have also recently weighed in on BGNE. 22nd Century Group reiterated a downgrade rating on […]
September 20, 2023
BeiGene welcomes the return of the immunotherapy’s rights as an opportunity to make it the backbone of its solid tumors strategy. But Novartis cedes an opportunity to gain a competitor to established cancer immunotherapies from Merck and Bristol Myers Squibb.
September 15, 2023
Abbott on August 18 had intimated the DCGI office regarding voluntary product recall of all batches of Digene Gel of all flavors (Mint, Orange, mix fruits flavor) which are within the self-life and manufactured at Goa facility
September 14, 2023
Earlier this month, regulator DCGI cautioned against the consumption of Digene Gel citing safety concerns even as the drug maker recalled several batches of the medicine manufactured at the Goa facility.
September 14, 2023
India's Goa state has warned the local unit of Abbott Laboratories it plans to suspend the manufacturing licence of its antacid medicine after inspectors flagged contamination risks and sanitization issues at its factory, government documents show. The U.S. based drugmaker is locked in a tussle with drug regulators in the tourist state of Goa in western India after the company, starting in August, voluntarily recalled many batches of its Digene Gel syrup produced there after it received cu...